Lithium oral solution Rx
Generic Name and Formulations:
Lithium ion 8mEq/5mL (equivalent to 300mg lithium carbonate); contains alcohol.
Roxane Laboratories, Inc.
Indications for Lithium oral solution:
Mania in bipolar disorder.
Individualize. Acute mania: 600mg 3 times daily. Usual maintenance: 300mg 3 or 4 times daily.
Renal or cardiovascular disease, concomitant diuretics, sodium depletion, severely debilitated or dehydrated: not recommended (if necessary, use low doses, monitor serum lithium levels daily, hospitalize).
Seizure disorders. Maintain adequate fluid and salt intake, esp. with fever, sweating, diarrhea, or infection. Monitor serum lithium levels frequently (toxic and therapeutic levels are close); draw blood for serum tests 8–12 hrs after previous dose. Monitor thyroid, renal function. Discontinue if diarrhea, vomiting, tremor, ataxia, drowsiness or weakness occur. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.
See Contraindications. Lithium toxicity potentiated by diuretics, ACE inhibitors, angiotensin II receptor blockers, carbamazepine, indomethacin, piroxicam (possibly other NSAIDs, including COX-2 inhibitors), metronidazole, calcium channel blockers: monitor and adjust lithium dose, if needed. Discontinue if signs of neurologic toxicity occur with neuroleptics (eg, haloperidol). Xanthines, acetazolamide, urea, alkalinizing agents may reduce serum lithium levels. Fluoxetine has variable effects on serum lithium levels. Prolongs effects of neuromuscular blockers. Hypothyroidism with chronic iodide administration. Serotonin syndrome with SSRIs.
Polyuria, polydipsia, drowsiness, tremor, hypothyroidism, extrapyramidal symptoms, GI upset, renal toxicity, seizures, arrhythmias, hypotension, lethargy, metallic taste, dry mouth, blurred vision, pseudotumor cerebri (discontinue if occurs).
Caps 150mg, 600mg—100; Caps 300mg—100, 1000; Tabs 300mg—100, 1000; Soln—500mL
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL